Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human lecithin-cholesterol acyltransferase
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Recombinant human lecithin-cholesterol acyltransferase (rhLCAT), also known as MEDI6012, is a biologic enzyme replacement therapy developed by AstraZeneca (MedImmune) for the treatment of cardiovascular diseases. LCAT is a plasma enzyme that catalyzes the esterification of unesterified cholesterol into cholesteryl esters, a critical step in the maturation of high-density lipoprotein (HDL) particles and the process of reverse cholesterol transport (RCT). By supplementing endogenous LCAT activity, MEDI6012 aims to enhance the removal of cholesterol from atherosclerotic plaques and improve lipid profiles. It has been investigated in Phase 2 clinical trials, including the REAL-TIMI 63B study, for indications such as acute ST-segment elevation myocardial infarction (STEMI) and stable atherosclerotic cardiovascular disease. Although it successfully increased HDL-cholesterol levels in clinical studies, it did not meet primary endpoints for reducing infarct size or regressing noncalcified coronary plaque in some trials.
- Brand names
- MEDI6012MEDI-6012MEDI 6012
- Other names
- rhLCATrecombinant human LCAT
02
Targets
APOA1 (Apolipoprotein A-I)Phosphatidylcholine (on High-Density Lipoprotein particles)
Beyond the preview
Go deeper on recombinant human lecithin-cholesterol acyltransferase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human lecithin-cholesterol acyltransferase.